Liquid Biopsies and Circulating Tumor DNA (ctDNA)

Liquid biopsies are a non-invasive method to detect cancer by analyzing circulating tumor DNA (ctDNA) in blood. ctDNA originates from cancer cells and offers real-time insights into tumor dynamics. This technique is valuable for early detection, monitoring treatment response, detecting minimal residual disease, and identifying resistance mutations. Unlike tissue biopsies, liquid biopsies can be repeated frequently with minimal discomfort. They are especially useful in tracking cancer progression and guiding personalized therapies. As technologies advance, liquid biopsies are becoming essential tools in precision oncology, offering a more dynamic and accessible approach to cancer diagnosis and management.

    Related Conference of Liquid Biopsies and Circulating Tumor DNA (ctDNA)

    June 16-17, 2025

    26th World Congress on Cancer Summit

    Amsterdam, Netherlands
    July 14-15, 2025

    5th World Congress on Breast Cancer

    Berlin, Germany
    July 28-29, 2025

    45th Euro Congress on Cancer Science & Therapy

    Paris, France
    August 18-19, 2025

    6th Cancer Diagnostics & Treatment Conference

    Rome, Italy
    October 20-21, 2025

    21st International Conference on Cancer Research

    Barcelona, Spain
    October 22-23, 2025

    35th Experts Meet On Cancer Research & Therapy

    Paris, France
    October 24-25, 2025

    25th World Congress on Cancer and Diagnostics

    Zurich, Switzerland
    November 24-25, 2025

    43rd World Cancer Conference

    Barcelona, Spain
    March 23-24, 2026

    16th World Congress on Breast Cancer Research & Therapies

    Aix-en-Provence, France

    Liquid Biopsies and Circulating Tumor DNA (ctDNA) Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in